Compared to patients with non-death, patients with death have higher baseline CTR, higher baseline AoAC, older age, higher smoking history, higher prevalence of diabetes mellitus, higher prevalence of coronary artery disease, higher prevalence of cerebrovascular disease, shorter duration of HD, lower albumin, higher fasting glucose, and higher percentage of antiplatelet agent use. This evidence concerns the gene ALB and cerebrovascular disorder.